


EU 490770840 US

In the Claims:

Please cancel claims 11-16 without prejudice. Applicants respectfully reserve the right to pursue the subject matter of these cancelled claims in the future.


Please amend claims 1-8 as follows:

1. A compound having a formula selected from the group consisting of:



or a pharmaceutically acceptable salt thereof.

2. A compound having a formula selected from the group consisting of:




2
436
B

or a pharmaceutically acceptable salt thereof.

3. A compound having the formula:

T,4310




or a pharmaceutically acceptable salt thereof.


B1

4. A compound having a formula selected from the group consisting of:

T,4311




and



or a pharmaceutically acceptable salt thereof.


5. A compound having the formula:

T,4312




or a pharmaceutically acceptable salt thereof.

6. A compound having a formula selected from the group consisting of:



and



or a pharmaceutically acceptable salt thereof.

β²
7. A pharmaceutical composition comprising: a therapeutically effective amount of a compound or pharmaceutically acceptable salt thereof as defined in any one of claims 1-6; and a pharmaceutically acceptable carrier or diluent.

8. A method for regulating the secretion of gonadotropins in mammals, comprising administering a therapeutically effective amount of a compound or pharmaceutically acceptable salt thereof as defined in any one of claims 1-6.